Catálogo de publicaciones - libros

Palabras clave – provistas por la editorial

benzofurans; chemical synthesis; cytotoxic properties; HeLa; MOLT-4; K562; anticancer; anti-neuroinflammation; coumarin; dihydroartemisinin; flavonoids; allene; E-stereoselective; regioselective; anti-cancer activity; cyanopyridone; substituted pyridine; pyridotriazine; pyrazolopyridine; thioxotriazopyridine; anticancer activity; HepG2; antitumor activity; computational docking; MDM2-p53 interaction; xanthones; yeast-based assays; estrone derivatives; hydrazine; N-substituted pyrazoline; anti-ovarian cancer; topoisomerase II inhibitor; kinase inhibitor; antiproliferative agent; urea; synthesis; antiproliferative activity; apoptosis; indoleamine 2,3-dioxygenase; inhibitor; anti-tumor; immune modulation; tryptophan metabolism; taxoids; βIII-tubulin; P-glycoprotein; drug resistance; thiopene; thienopyrimidinone; thiazolidinone; breast cancer; benzofuran–pyrazole; nanoparticles; cytotoxic activity; PARP-1 inhibition; 3,6-dibromocarbazole; 5-bromoindole; carbazole; actin; migration; Thienopyrimidine; Pyrazole; PI3Kα inhibitor; quinazolin-4(3H)-one; quinazolin-4(3H)-thione; Schiff base; antioxidant activity; DFT study; ortho-quinones; beta-lapachone; tanshione IIA; PI3Ks; PI3Kδ inhibitors; 2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide; anticancer agents; protein–protein interactions; virtual screening; mimetics; drug discovery; bivalency; polyvalency; antitumor; cell cycle; ovarian cancer; P-MAPA; IL-12; TLR signaling; inflammation; chemoresistance; 4-(pyridin-4-yloxy)benzamide; 1,2,3-triazole; c-Met; natural product; anticancer agent; zampanolide; Talazoparib; PARP inhibitor; prodrug; o-nitro-benzyl; photoactivatable protecting groups; salinomycin; overcoming drug resistance; tumor specificity; synergy; 5-fluorouracil; gemcitabine; amides/esters; colchicine analogs; thiocolchicine; colchiceine; antimitotic agents; hydrates; dihydropyranoindole; HDAC inhibitors; neuroblastoma; aromatase; MCF-7; NIH3T3; benzimidazole; triazolothiadiazine; docking; ADME; organosilicon compounds; SILA-409 (Alis-409); SILA-421 (Alis-421); multidrug resistance (MDR) reversal; ABCB1 (P-glycoprotein); colon cancer; colchicine amide; colchicine sulfonamide; tubulin inhibitors; docking studies; crystal structure; PROTACs; protein degradation; IGF-1R; Src; protein kinase; phenylpyrazolopyrimidine; enzyme inhibition; molecular simulation; androgen receptor; prostate cancer; enzalutamide; apalutamide; darolutamide; triple-negative breast cancer; cytotoxicity; chrysin analogues; flavonoid; anticancer compounds